EARNEST Partners
TARO

EARNEST Partners’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

EARNEST Partners’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed – – 1226
2018
Q3 		$0 Hold
2
– – ﹤0.01% 1203
2018
Q2 		$0 Hold
2
– – ﹤0.01% 1239
2018
Q1 		$0 Hold
2
– – ﹤0.01% 1216
2017
Q4 		$0 Buy
+2
New +$220 ﹤0.01% 1214

Other funds holding TARO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return

EARNEST Partners's TARO Position: Q4 2018 in Review

EARNEST Partners sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2018, closing a stake of 2 shares.

EARNEST Partners first reported a position in TARO in Q4 2017 and held it in 4 quarters. The position peaked at $0 in Q3 2018. 94 funds tracked by Wall St. Rank hold TARO as of Q4 2018.

  • EARNEST Partners reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2018 after selling out during the quarter.
  • EARNEST Partners sold 2 Taro Pharmaceutical Industries Ltd. shares in Q4 2018.
  • EARNEST Partners first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2017 and held it in 4 quarters.
  • EARNEST Partners's Taro Pharmaceutical Industries Ltd. position peaked at $0 in Q3 2018.
  • 94 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2018.

Based on EARNEST Partners's 13F filing for Q4 2018, filed 14 Feb 2019.